share_log

Thomas J. Schuetz Purchases 20,000 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock

Defense World ·  Feb 2, 2023 04:52

Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) CEO Thomas J. Schuetz purchased 20,000 shares of Compass Therapeutics stock in a transaction on Tuesday, January 31st. The stock was bought at an average price of $4.05 per share, for a total transaction of $81,000.00. Following the completion of the acquisition, the chief executive officer now owns 5,471,873 shares in the company, valued at approximately $22,161,085.65. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Compass Therapeutics Trading Down 0.2 %

CMPX stock opened at $3.99 on Thursday. Compass Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $5.65. The company has a 50-day moving average price of $4.64 and a 200 day moving average price of $3.63. The stock has a market cap of $503.50 million, a PE ratio of -9.50 and a beta of 1.36.

Get Compass Therapeutics alerts:

Compass Therapeutics (NASDAQ:CMPX – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($0.12) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.01). Sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.39 EPS for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Compass Therapeutics in a report on Tuesday. They issued a "buy" rating and a $8.00 price target on the stock. LADENBURG THALM/SH SH boosted their target price on shares of Compass Therapeutics to $9.00 in a report on Wednesday, November 16th. Raymond James boosted their target price on shares of Compass Therapeutics from $5.00 to $8.00 and gave the stock an "outperform" rating in a report on Thursday, November 10th. HC Wainwright reduced their target price on shares of Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Thursday, November 3rd. Finally, EF Hutton Acquisition Co. I started coverage on shares of Compass Therapeutics in a report on Friday, December 16th. They issued a "buy" rating and a $10.30 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $9.05.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $33,000. Bank of New York Mellon Corp purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $55,000. Marshall Wace LLP boosted its position in Compass Therapeutics by 118.4% in the 3rd quarter. Marshall Wace LLP now owns 51,816 shares of the company's stock valued at $117,000 after buying an additional 28,089 shares during the period. Renaissance Technologies LLC boosted its position in Compass Therapeutics by 397.5% in the 2nd quarter. Renaissance Technologies LLC now owns 66,165 shares of the company's stock valued at $175,000 after buying an additional 52,865 shares during the period. Finally, Silverarc Capital Management LLC purchased a new stake in Compass Therapeutics in the 3rd quarter valued at about $598,000. 54.27% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

(Get Rating)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137.

See Also

  • Get a free copy of the StockNews.com research report on Compass Therapeutics (CMPX)
  • Bed Bath & Beyond Is Circling the Drain
  • Allegro Microsystems Is A Well-Positioned Semiconductor Stock
  • Scotts Miracle-Gro Hits Bottom, Reversal In Play
  • Altria is a Great Recession Stock, Long-Term Outlook Uncertain
  • Novavax Shares Jumped in January While Others Slipped

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment